Tevogen Bio Holdings Inc

Insider Trading Arrangements

During the three months ended June 30, 2024, none of our directors or officers adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Elimination of Series B Preferred Stock

On August 9, 2024, the Company filed a Certificate of Elimination of Series B Preferred Stock (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The Series B Preferred Stock had been designated pursuant to the Certificate of Designation of Series B Preferred Stock filed with the Secretary of State of the State of Delaware on March 15, 2024. As of the date of the filing of the Certificate of Elimination, no shares of Series B Preferred Stock were outstanding. Upon filing the Certificate of Elimination, the 3,613 shares of Series B Preferred Stock were returned to the status of authorized but unissued shares of preferred stock of the Company, without designation as to series or rights, preferences, privileges, or limitations.

The foregoing summary of the Certificate of Elimination is qualified by reference to the full text of the Certificate of Elimination, which is filed as Exhibit 3.1 to this Quarterly Report on Form 10-Q and incorporated herein by reference.